daurismo
pfizer europe ma eeig - glasdegib maleate - leukæmi, myeloid, akut - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
ropivacaine "bioq" 2 mg/ml infusionsvæske, opløsning i administrationssystem
bioq pharma b.v. - ropivacainhydrochloridmonohydrat - infusionsvæske, opløsning i administrationssystem - 2 mg/ml
sabrilex 500 mg granulat til oral opløsning
sanofi a/s - vigabatrin - granulat til oral opløsning - 500 mg
brevibloc 10 mg/ml injektionsvæske, opløsning
baxter a/s - esmololhydrochlorid - injektionsvæske, opløsning - 10 mg/ml
dacepton 10 mg/ml injektionsvæske, opløsning i cylinderampul
ever neuro pharma gmbh - apomorphinhydrochlorid hemihydrat - injektionsvæske, opløsning i cylinderampul - 10 mg/ml
dropizol 10 mg/ml orale dråber, opløsning
pharmanovia a/s - opium - orale dråber, opløsning - 10 mg/ml
natriumklorid "baxter" viaflo 9 mg/ml infusionsvæske, opløsning
baxter a/s - natriumchlorid - infusionsvæske, opløsning - 9 mg/ml
olumiant
eli lilly nederland b.v. - baricitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan anvendes som monoterapi eller i kombination med methotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
bicavera 1,5% glucose, 1,75 mmol/l calcium peritonealdialysevæske, opløsning
fresenius medical care deutschland gmbh - calciumchlorid, vandfrit, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske, opløsning
bicavera 2,3% glucose, 1,75 mmol/l calcium peritonealdialysevæske, opløsning
fresenius medical care deutschland gmbh - calciumchlorid, vandfrit, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske, opløsning